Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome

Abstract

Patients with clinical features of MEN 1 without mutations in the menin gene fulfill the criteria of MEN1-like syndrome. Primary hyperparathyroidism (PHP) is the most frequent clinical finding in both syndromes and is usually treated by surgery. However, PHP has been reported to respond to somatostatin analogues (SSA) in MEN 1 patients. 7 patients with PHP in the context of MEN 1-like syndrome (and absence of mutations in the menin gene) were enrolled in the study and treated with SSA for 6 months for the non-PHP disease before parathyroidectomy. Serum ionized calcium, phosphorus, and PTH concentrations, and 24-h urinary calcium and phosphorus excretion were measured before and after SSA therapy. Mean serum ionized calcium, phosphorus, and PTH concentrations did not significantly change after a 6-month course with SSA. SSA scintigraphy did not reveal uptake in the neck region corresponding to the parathyroid adenoma identified at surgery and confirmed at histology. However, immunohistochemistry revealed SS-type 2A receptor in parathyroid tissue samples of 6 out of 7 patients. SSA therapy does not affect calcium-phosphorus metabolism in patients with MEN 1-like syndrome, suggesting that the drug has no role in controlling PHP in these subset of patients.

acromegaly - somatostatin analogues - hyperparathyroidism - MEN 1-like

References

• 1 Brandi ML, Gagel RF, Angeli A, John P, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips JMP, Lombardi G, Mannelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Marx SJ. Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2.  J Clin Endocrinol Metab. 2001;  86 5658-5671
• 2 Marini F, Carbonell Sala S, Falchetti A, Caramelli D, Brandi ML. The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis.  J Endocrinol Invest. 2008;  31 905-909
• 3 Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia.  J Clin Endocrinol Metab. 2007;  92 3321-3325
• 4 Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.  Proc Natl Acad Sci (USA). 2006;  103 15558-15563
• 5 Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.  J Clin Endocrinol Metab. 2009;  94 1826-1834
• 6 Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G. Somatostatin receptor subtypes: basic pharmacology and tissue distribution.  Dig Liver Dis. 2004;  36 8-16
• 7 Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.  Clin Endocrinol. 2008;  69 756-762
• 8 Akerström G, Stålberg P. Surgical management of MEN-1 and -2: state of the art.  Surg Clin North Am. 2009;  89 1047-1068
• 9 Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML. Surgical approach in hereditary hyperparathyroidism.  Endocr J. 2009;  56 827-841
• 10 Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.  J Endocrinol Invest. 2008;  31 820-838
• 11 Krennings EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.  Digestion. 1994;  55 (S 39) 54-59
• 12 Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A, Osamura RY. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide.  Endocr Pathol. 2007;  18 208-216
• 13 Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2° immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.  Mod Pathol. 2007;  20 1172-1182
• 14 Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy.  Front Horm Res. 2004;  32 235-252
• 15 Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.  Eur J Endocrinol. 2005;  152 757-767
• 16 Boulahdour H, Bertrand A, Klingelschmitt S, Rudenko B, Loboguerrero A, Bidet A, Mation G, Cardot J. Parathyroid adenoma visualization on Octreotide Scintigraphy.  Clin Nucl Med. 2002;  27 304-305
• 17 Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.  Clin Endocrinol. 1997;  47 589-598
• 18 Dreijerink KM, Lips CJ, Timmers HT. Multiple endocrine neoplasia type 1: a chromatin writer's block.  J Intern Med. 2009;  266 53-59
• 19 Hublitz P, Albert M, Peters AHFM. Mechanisms of transcriptional repression by histone lysine methylation.  Int J Dev Biol. 2009;  53 335-354
• 20 Ybarra J, Moisès J, Torregrosa JV, Madhun ZT, Schumacher OP. Effects of octreotide on serum and urine electrolytes in a patient with a parathyroid carcinoma: clinical case.  Nefrologia. 2001;  21 406-410

Notice:

The title was changed after e-first publication to “Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome”.

Correspondence